"Poststroke Depression"

Huff, Wolfgang; Steckel, Richard J.; Sitzer, Matthias

doi:10.1007/s00115-002-1417-x

Cited by 45 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…У большинства пациентов депрессия развивается в первые 3-6 месяцев после инсульта [9,10,11], также описаны случаи развития депрессии в остром периоде инсульта -в течение первых 7-10 суток [12]. Лишь у 12% она впервые выявляется через 12-18 месяцев после сосудистой катастрофы [9,13]. Чаще всего постинсультная депрессия (72%) регистрируется именно в позднем восстановительном периоде инсульта [14].…”

Section: факторы риска возникновения инсультаunclassified

Факторы Риска И Особенности Депрессивных Нарушений У Больных, Перенесших Мозговой Инсульт

Хомячук,

Вербах,

Остапчук

et al. 2023

АЖЗС

View full text Add to dashboard Cite

The article presents a review of literature data on relevance, pathogenetic mechanisms, risk factors for stroke and post-stroke depression. There are given epidemiological data on the prevalence of this pathological condition, as well as factors contributing to its development. The main patterns of development of depressive disorder in patients with cerebral stroke are listed. The authors analyze relationship of depression with the localization of the pathological focus in the brain, the affected vascular pool, as well as the possible mechanisms for the development of post-stroke depression from the point of view of neurotransmitter systems.

show abstract

Section: факторы риска возникновения инсультаunclassified

Факторы Риска И Особенности Депрессивных Нарушений У Больных, Перенесших Мозговой Инсульт

Хомячук,

Вербах,

Остапчук

et al. 2023

АЖЗС

View full text Add to dashboard Cite

show abstract

“…Poststroke depression (PSD) is a serious complication of cerebrovascular disease, which is frequently observed within three to six months following stroke onset, with an incidence of approximately 22–75% [ 1 ]. Patients not only have symptoms related to autonomic nervous system and other physiological distress, but also have depression-associated emotional symptoms.…”

Section: Introductionmentioning

confidence: 99%

A Network Meta-Analysis of the Clinical Efficacy and Safety of Commonly Used Chinese Patent Medicines in the Auxiliary Treatment of Poststroke Depression

Zhang²,

Han

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Poststroke depression (PSD) is a serious complication of clinical cerebrovascular disease. Patients not only have depression-related emotional symptoms but also have physical symptoms, such as autonomic dysfunction. At the same time, patients with varying degrees of depression will delay the neurological function of stroke patients. The recovery time of cognitive function and limb function will increase the risk of accidental death and even aggravate the mortality of cerebrovascular disease. Through combining data analysis and related literature, seven types of Chinese patent medicines (CPMs) widely used in the clinical treatment of PSD have been screened out. These herbs exhibit some clinical comparability under the conditions that the syndrome type and dosage form are relatively uniform. Therefore, in this study, the network meta-analysis method was used to evaluate the safety and efficacy of the seven CPMs screened out, and the probability ranking was performed to screen the best clinical auxiliary treatment plan of CPM. Methods. We searched the Chinese databases, including CNKI, WANFANG, and VIP, as well as the English databases, including the Cochrane Library, EMBASE, and PubMed, from inception to May 31, 2020, to identify randomized controlled trials (RCTs) on seven kinds of CPMs that were the subjects of the clinical research. The bias risk and quality of the included studies were analyzed with the Cochrane Handbook (version 5.1), ADDIS, and R software, and the results were compared in a network meta-analysis (NMA). Results. In terms of clinical effectiveness, the seven kinds of CPMs all improved clinical curative effects, with Jieyu Anshen capsule adjuvant treatment having the most significant effect [odds ratio (OR) = 5.00, 95% CI (1.72–9.48)]. Wuling capsule AT can effectively reduce the score index of scale factors for the HAMD score, NIHSS score, and TESS score [mean difference (MD) = −3.95, 95% CI (−4.88–3.00); OR = −3.25, 95% CI (−5.46)–1.05); OR = 0.22, 95% CI (0.05–0.79), resp.]. Conclusion. The mechanisms of seven CPMs in the adjuvant treatment of PSD have advantages. In terms of safety and efficacy, the CPMs had better clinical adjuvant treatment performance. Although this study concluded that the Jieyu Anshen capsule is the preferred drug for clinical treatment, a clear conclusion still needs to be verified in a high-quality randomized controlled study. In clinical practice, accurate selection and application can be carried out according to the specific characteristics of patients.

show abstract

“…Further causes include an overdose of digitalis, psychoactive drugs, or multiple agents at once (7). Left-hemispheric cerebral ischemia can lead to post-stroke depression with loss of drive and reduced appetite (8). These patients stand to benefit from antidepressive treatment.…”

Section: Somatic Causes Of Behavioral Disorders In Dementiamentioning

confidence: 99%

“…The right treatment in such cases is to stop the drug. Left-hemispheric cerebral ischemia can cause an organic affective disturbance (8) with affect lability and agitation, or else an organic delusional disorder (e.g., with delusions of being a victim of poisoning or theft) and aggressiveness.…”

Section: Somatic Causes Of Behavioral Disorders In Dementiamentioning

confidence: 99%